Contradictions in off-label prescription of aspirin for primary preventionfemme

Context. In family medicine, 9.6% Of off-label prescriptions involve aspirin. However, the prescription guidelines are inconsistent. While the marketing authorization for aspirin only includes indications for secondary preventative treatment, the national health insurance fund encourages its prescription for primary preventative treatment through the pay for performance program. The aim of this study was to explore the inconsistencies between the prescription guidelines for aspirin and its marketing authorization. Method. A case study based on open interviews with the institutional agencies involved in prescribing aspirin. Thematic analysis using open coding. Results. A lack of consultation between the institutional agencies regarding the marketing authorization procedures was observed. We also observed widespread variation among the solutions proposed to reduce off-label prescription. The disparity of solutions reflected the inconsistencies concerning aspirin prescription in primary preventative treatment. Conclusion. A reform of the extension of the marketing authorization process seems necessary when use of a drug is validated by medical associations.